Story perspectives

New mRNA Vaccine Method Promises Safer, Stronger Immune Response

10/16/2025

23 4

Summary

Story summary

Researchers from the National University of Singapore and Tsinghua University developed a mRNA vaccine delivery method using albumin-recruiting lipid nanoparticles, EB-LNPs.
EB-LNPs direct mRNA to lymph nodes and avoid liver accumulation, reducing toxicity.
Laboratory tests show EB-LNPs outperform traditional lipid nanoparticles in eliciting immune responses against cancer and viral infections.
The team plans to move to clinical trials to assess human safety and efficacy and broaden mRNA vaccine design.

1 of 1

Story summary

Researchers from the National University of Singapore and Tsinghua University developed a mRNA vaccine delivery method using albumin-recruiting lipid nanoparticles, EB-LNPs.
EB-LNPs direct mRNA to lymph nodes and avoid liver accumulation, reducing toxicity.
Laboratory tests show EB-LNPs outperform traditional lipid nanoparticles in eliciting immune responses against cancer and viral infections.
The team plans to move to clinical trials to assess human safety and efficacy and broaden mRNA vaccine design.